8-K - BTAI - Equibles

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) ofthe

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) February 12, 2024

BioXcel

Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware	001-38410	82-1386754
(State<br> or other jurisdiction of<br><br> incorporation)	(Commission<br> File Number)	(IRS<br> Employer<br> Identification No.)

555

Long Wharf Drive

New

Haven, CT 06511

(Address of principal executive offices, including Zip Code)

(475

)

238-6837

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written<br> communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨	Soliciting<br> material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
---	---
¨	Pre-commencement<br> communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
---	---
¨	Pre-commencement<br> communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
---	---

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common<br> Stock, par value $0.001	BTAI	The Nasdaq<br> Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 1.01	Entry into a Material Definitive Agreement.

The Third Amendment to Credit Agreement and Guaranty

On February 12, 2024, BioXcel Therapeutics, Inc. (the “Company”) entered into the Third Amendment to Credit Agreement and Guaranty (the “Third Amendment”), which amended the Credit Agreement and Guaranty, dated April 19, 2022, by and among the Company, as the borrower, certain subsidiaries of the Company from time to time party thereto as subsidiary guarantors, the lenders party thereto (the “Lenders”), and Oaktree Fund Administration LLC (“OFA”) as administrative agent (as amended by the Waiver and First Amendment to Credit Agreement and Guaranty, dated as of November 13, 2023, and the Second Amendment to Credit Agreement and Guaranty and Termination of Revenue Interest Financing Agreement, dated as of December 5, 2023, the “Existing Credit Agreement”). Pursuant to the Third Amendment, the Lenders agreed to waive the covenant that the Company shall not receive a report and opinion from the Company’s independent auditors that contains a “going concern” or like qualification or exception or emphasis of matter of going concern footnote with respect to the Company’s financial statements for the fiscal year ended December 31, 2023 and, as a result, such event shall not be an event of default. As a condition to the effectiveness of the Third Amendment, among other things, the Company shall have received at least $40.0 million in gross proceeds from a registered public sale of the Company’s common stock, warrants and/or pre-funded warrants.

The foregoing summary of the Third Amendment is qualified in its entirety by the complete text of such agreement, a copy of which is filed hereto as Exhibit 10.1.

Item 8.01	Other Events.

On February 12, 2024, the Company announced that the U.S. Food and Drug Administration designated as a Fast Track development program the investigation of BXCL701 in combination with a checkpoint inhibitor for the treatment of patients with metastatic small cell neuroendocrine prostate cancer with progression on chemotherapy and no evidence of microsatellite instability.

Item 9.01.	Financial Statements and Exhibits.

(d) Exhibits:

ExhibitNo.	Description
10.1	Third Amendment to Credit Agreement and Guaranty dated February 12, 2024, which amended the Credit Agreement and Guaranty, dated April 19, 2022, by and among the Company, as the borrower, certain subsidiaries of the Company from time to time party thereto as subsidiary guarantors, the lenders party thereto, and Oaktree Fund Administration LLC, as administrative agent (as amended by the Waiver and First Amendment to Credit Agreement and Guaranty, dated as of November 13, 2023 and the Second Amendment to Credit Agreement and Guaranty and Termination of Revenue Interest Financing Agreement dated as of December 5, 2023)
104	Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)

ExhibitNo.

Description

10.1

Third Amendment to Credit Agreement and Guaranty dated February 12, 2024, which amended the Credit Agreement and Guaranty, dated April 19, 2022, by and among the Company, as the borrower, certain subsidiaries of the Company from time to time party thereto as subsidiary guarantors, the lenders party thereto, and Oaktree Fund Administration LLC, as administrative agent (as amended by the Waiver and First Amendment to Credit Agreement and Guaranty, dated as of November 13, 2023 and the Second Amendment to Credit Agreement and Guaranty and Termination of Revenue Interest Financing Agreement dated as of December 5, 2023)

104

Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 12, 2024	BIOXCEL THERAPEUTICS, INC.
	/s/ Richard Steinhart
	Richard Steinhart
	Chief Financial Officer

Exhibit 10.1

THIRDAMENDMENT TO Credit agreement AND guaranty

EXECUTION VERSION

This Third Amendment to Credit Agreement and Guaranty (this “Amendment”) is made as of February 12, 2024, by and among BIOXCEL THERAPEUTICS, INC., a Delaware corporation (the “Borrower”), the lenders party hereto (collectively, the “Lenders” and individually, a “Lender”), and OAKTREE FUND ADMINISTRATION, LLC, as administrative agent on behalf of the Lenders (in such capacity, together with its successors and assigns, the “Administrative Agent”).

WHEREAS, the Borrower, the Administrative Agent and the Lenders previously entered into that certain Credit Agreement and Guaranty, dated as of April 19, 2022 (including the exhibits and other attachments thereto, as amended by that certain Waiver and First Amendment to Credit Agreement and Guaranty, dated as of November 13, 2023 and that certain Second Amendment to Credit Agreement and Guaranty and Termination of Revenue Interest Financing, dated as of December 5, 2023, the “Existing Credit Agreement”, and as further amended by this Amendment, the “Credit Agreement”);

WHEREAS, the Borrower, the Administrative Agent and the Lenders have agreed to amend the Existing Credit Agreement on the terms and subject to the conditions set forth herein.

NOW, THEREFORE, for and in consideration of the above premises and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged by the parties hereto, each of the Borrower, the Administrative Agent and the Lenders party hereto hereby covenant and agree as follows:

1.	Definitions.<br> Capitalized terms used herein and not otherwise defined herein shall have the meanings assigned<br> to such terms in the Existing Credit Agreement.

2.             Amendment. Subject to the satisfaction of the conditions precedent specified in Section 4 hereof and the condition subsequent specified in Section 5 hereof, Section 8.01(b) of the Existing Credit Agreement shall be deleted in its entirety and replaced as follows:

“(b)             as soon as available and in any event within ninety (90) days after the end of each fiscal year (i) the consolidated balance sheets of the Borrower and its Subsidiaries as of the end of such fiscal year and (ii) the related consolidated statements of income, stockholders’ equity and cash flows of the Borrower and its Subsidiaries for such fiscal year, in each case prepared in all material respects in accordance with GAAP consistently applied, all in reasonable detail and setting forth in comparative form the figures for the previous fiscal year, accompanied by a report and opinion thereon of Ernst & Young U.S. LLP or another firm of independent certified public accountants of recognized national standing reasonably acceptable to the Administrative Agent, which report and opinion shall be prepared in accordance with generally accepted auditing standards and such report and opinion shall not be subject to (x) except with respect to the report and opinion delivered for the fiscal year ending on December 31, 2023, any “going concern” or like qualification or exception or emphasis of matter of going concern footnote or (y) any qualification or exception as to the scope of such audit, and in the case of such consolidated financial statements, certified by a Responsible Officer of the Borrower; provided that documents required to be furnished pursuant to this Section 8.01(b) shall be deemed furnished on the date that such documents are publicly available on “EDGAR”;”.

3.	Reaffirmation<br> of Loan Documents. Except as otherwise expressly provided herein, the parties hereto<br> agree that all terms and conditions of the Existing Credit Agreement and the other Loan Documents<br> remain in full force and effect. The Borrower hereby confirms that the Security Documents<br> and all of the Collateral described therein do, and shall continue to, secure the payment<br> in full and performance of all of the Obligations.
4.	Conditions<br> Precedent to Effectiveness. The effectiveness of this Amendment shall be subject to the<br> following conditions precedent:
---	---
(a)	This<br> Amendment shall have been duly executed and delivered to the Administrative Agent by the<br> Borrower and the Lenders, which constitute the “Majority Lenders” as defined<br> in the Existing Credit Agreement;
---	---
(b)	Each<br> of the representations and warranties in Section 6 of this Amendment, Section 7<br> of the Credit Agreement and in the other Loan Documents shall be true, accurate and complete<br> in all material respects (unless such representations are already qualified by reference<br> to materiality, Material Adverse Effect or similar language, in which case such representations<br> and warranties shall be true and correct in all respects) on and as of the date hereof with<br> the same effect as though made on and as of such date, except to the extent such representations<br> and warranties expressly relate to an earlier date, in which case such representations and<br> warranties shall have been true and correct in all respects on and as of such earlier date;<br> and
---	---
(c)	At<br> the time of and after giving effect to this Amendment, no fact or condition exists that constitutes,<br> or with the passage of time, the giving of notice, or both, would constitute, a Default or<br> Event of Default.
---	---
(d)	Condition<br> Subsequent to Effectiveness. In addition to the conditions precedent set forth in the<br> preceding Section 4, the effectiveness of this Amendment shall be subject to (i) the<br> Borrower’s receipt after the date hereof and on or before February 20, 2024 of<br> at least $40,000,000 in gross proceeds from a registered public sale of Borrower’s<br> common stock, warrants and/or pre-funded warrants (excluding any investor previously agreed<br> between the Company and the Agent) and (ii) the Borrower shall have paid all costs,<br> fees and expenses of the Administrative Agent and the Lenders, including, without limitation,<br> the fees and expenses of Sullivan & Cromwell LLP, as outside counsel to Administrative<br> Agent and the Oaktree Lenders, and the fees and expenses of Shearman & Sterling<br> LLP, as outside counsel to Q Boost Holding LLC, incurred in connection herewith.
---	---
5.	Representations<br> and Warranties. The Borrower hereby represents and warrants:
---	---
(a)	None<br> of the execution, delivery and performance by the Borrower of this Amendment and the documents,<br> instruments and agreements executed in connection herewith (collectively, the “Amendment Documents”) or performance under the Amendment Documents (i) requires any<br> Governmental Approval of, registration or filing with, or any other action by, any Governmental<br> Authority or any other Person, except for (x) such as have been obtained or made and<br> are in full force and effect and (y) filings and recordings in respect of perfecting<br> or recording the Liens created pursuant to the Security Documents, (ii) will violate<br> (1) any Law, (2) any Organic Document of the Borrower or any of its Subsidiaries<br> or (3) any order of any Governmental Authority, that in the case of clause (ii)(1) or<br> clause (ii)(3), individually or in the aggregate, would reasonably be expected to<br> result in a Material Adverse Effect, (iii) will violate or result in a default under<br> any Material Agreement binding upon the Borrower or any of its Subsidiaries that, individually<br> or in the aggregate, would reasonably be expected to result in a Material Adverse Effect<br> or (iv) will result in the creation or imposition of any Lien (other than Permitted<br> Liens) on any asset of the Borrower or any of its Subsidiaries.
---	---
(b)	This<br> Amendment and the other Amendment Documents have been duly authorized by all necessary corporate<br> or other organizational action including, if required, approval by all necessary holders<br> of Equity Interests, and duly executed and delivered by the Borrower and constitutes, and<br> each of the Amendment Documents when executed and delivered by the Borrower will constitute,<br> a legal, valid and binding obligation of the Borrower, enforceable against the Borrower in<br> accordance with its terms, except as such enforceability may be limited by (i) bankruptcy,<br> insolvency, reorganization, moratorium or similar laws of general applicability affecting<br> the enforcement of creditors’ rights and (ii) the application of general principles<br> of equity (regardless of whether such enforceability is considered in a proceeding in equity<br> or at law).
---	---
6.	Release.
---	---
(a)	In<br> consideration of this Amendment and agreements of the Administrative Agent and the Lenders<br> contained herein and for other good and valuable consideration, the receipt and sufficiency<br> of which is hereby acknowledged, the Borrower (the “Releasing Party”),<br> on behalf of itself and its successors, assigns and other legal representatives hereby absolutely,<br> unconditionally and irrevocably releases, remises and forever discharges the Administrative<br> Agent and the Lenders and their respective present and former shareholders, affiliates, subsidiaries,<br> divisions, predecessors, directors, officers, attorneys, employees, agents and other representatives,<br> in each case solely in their capacities relative to the Lenders and not in any other capacity<br> such party may have relative to the Releasing Party (the Administrative Agent, each Lender<br> and all such other Persons being hereinafter referred to collectively as the “Releasees”<br> and individually as a “Releasee”), of and from all demands, actions,<br> causes of action, suits, covenants, contracts, controversies, agreements, promises, sums<br> of money, accounts, bills, reckonings, damages and any and all other claims, counterclaims,<br> defenses, rights of set-off, demands and liabilities whatsoever of every name and nature,<br> known or unknown, suspected or unsuspected, both at law and in equity, which the Borrower<br> or any of its successors, assigns or other legal representatives may now or hereafter own,<br> hold, have or claim to have against the Releasees or any of them for, upon, or by reason<br> of any circumstance, action, cause or thing whatsoever which arises at any time on or prior<br> to the date hereof, for or on account of, or in relation to, or in any way in connection<br> with the Credit Agreement or any of the other Loan Documents or transactions thereunder (any<br> of the foregoing, a “Claim” and collectively, the “Claims”).<br> The Releasing Party expressly acknowledges and agrees, with respect to the Claims, that it<br> waives, to the fullest extent permitted by applicable law, any and all provisions, rights<br> and benefits conferred by any applicable U.S. federal or state law, or any principle of U.S.<br> common law, that would otherwise limit a release or discharge of any unknown Claims pursuant<br> to this Section 7. Furthermore, the Releasing Party hereby absolutely, unconditionally<br> and irrevocably covenants and agrees with and in favor of each Releasee that it will not<br> sue (at law, in equity, in any regulatory proceeding or otherwise) any Releasee on the basis<br> of any Claim released and/or discharged by the Releasing Parties pursuant to this Section 7.<br> The foregoing release, covenant and waivers of this Section 7 shall survive and remain<br> in full force and effect regardless of the consummation of the transactions contemplated<br> hereby, the repayment or prepayment of any of the Loans, or the termination of the Credit<br> Agreement, this Amendment, any other Loan Document or any provision hereof or thereof.
---	---
(b)	Each<br> Releasing Party understands, acknowledges and agrees that its release set forth above may<br> be pleaded as a full and complete defense and may be used as a basis for an injunction against<br> any action, suit or other proceeding which may be instituted, prosecuted or attempted in<br> breach of the provisions of such release.
---	---
(c)	Each<br> Releasing Party agrees that no fact, event, circumstance, evidence or transaction which could<br> now be asserted or which may hereafter be discovered shall affect in any manner the final,<br> absolute and unconditional nature of the release set forth above.
---	---
7.	Fees<br> and Expenses. The Borrower agrees to pay on demand (a) all out-of-pocket fees, costs<br> and expenses of the Administrative Agent and the Lenders accrued prior to the date hereof<br> and (b) all out-of-pocket fees, costs and expenses of the Administrative Agent and the<br> Lenders incurred in connection with the preparation, execution and delivery of (i) this<br> Amendment, (ii) any Amendment Documents, other Loan Documents or other post-closing<br> amendments, agreements, arrangements or documentation, (iii) any other instruments and<br> documents to be delivered hereunder or thereunder, in each case of clauses (a) and (b),<br> including the fees and expenses of Sullivan & Cromwell LLP, as outside counsel to<br> Administrative Agent and the Oaktree Lenders, and Shearman & Sterling LLP, as outside<br> counsel to Q Boost Holding LLC, with respect thereto.
---	---
8.	Miscellaneous.
---	---
(a)	Except<br> as otherwise expressly provided herein, all provisions of the Credit Agreement and the other<br> Loan Documents remain in full force and effect. This Amendment shall constitute a Loan Document.
---	---
(b)	This<br> Amendment may be executed in several counterparts and by each party on a separate counterpart,<br> each of which when so executed and delivered shall be an original, and all of which together<br> shall constitute one instrument. An executed facsimile or electronic copy of this Amendment<br> shall be effective for all purposes as an original hereof.
---	---
(c)	This<br> Amendment expresses the entire understanding of the parties with respect to the amendments<br> contemplated hereby. No prior negotiations or discussions shall limit, modify, or otherwise<br> affect the provisions hereof.
---	---
(d)	This<br> Amendment and its contents shall be subject to the governing law, indemnification, venue,<br> service of process, waivers of jury trial and severability provisions of the Existing Credit<br> Agreement, mutatis mutandis.
---	---

[SIGNATURE PAGES FOLLOW]

IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed and delivered as of the day and year first above written.

BORROWER:
BIOXCEL THERAPEUTICS, INC.
By:	/s/<br> Vimal Mehta
Name:	Vimal Mehta
Title:	Chief Executive Officer
Address for Notices:<br><br> <br>555 Long Wharf Drive, 12th Floor<br><br> New Haven, CT<br><br> <br>06511<br><br> <br><br><br> <br>With a copy to (which shall not constitute notice):<br><br> <br><br><br> <br>Cooley LLP<br><br> <br>3 Embarcadero Center<br><br> 20th Floor<br><br> <br>San Francisco, CA 94111-4004<br><br> <br>Attn: Mischi a Marca<br><br> <br>Email: gmamarca@cooley.com